Concepts (273)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Angiotensin, Type 2 | 28 | 2023 | 28 | 11.150 |
Why?
|
| Kidney | 14 | 2024 | 53 | 4.420 |
Why?
|
| Hypertension | 13 | 2022 | 61 | 4.000 |
Why?
|
| Obesity | 16 | 2023 | 118 | 3.800 |
Why?
|
| Blood Pressure | 13 | 2021 | 40 | 3.290 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 15 | 2.570 |
Why?
|
| Kidney Tubules, Proximal | 18 | 2024 | 27 | 2.470 |
Why?
|
| Renin-Angiotensin System | 8 | 2023 | 11 | 2.390 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2020 | 14 | 2.360 |
Why?
|
| Animals | 43 | 2024 | 1817 | 2.160 |
Why?
|
| Receptor, Angiotensin, Type 1 | 14 | 2023 | 15 | 2.120 |
Why?
|
| Kidney Diseases | 4 | 2024 | 11 | 2.100 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2020 | 9 | 1.850 |
Why?
|
| Rats | 28 | 2023 | 251 | 1.720 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 2 | 2024 | 7 | 1.680 |
Why?
|
| Lipopolysaccharides | 3 | 2023 | 15 | 1.530 |
Why?
|
| Rats, Zucker | 17 | 2023 | 20 | 1.490 |
Why?
|
| Proteinuria | 3 | 2023 | 10 | 1.480 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 6 | 2017 | 6 | 1.480 |
Why?
|
| Inflammation | 4 | 2020 | 59 | 1.460 |
Why?
|
| Peptide Fragments | 4 | 2020 | 12 | 1.410 |
Why?
|
| Nitric Oxide | 3 | 2020 | 11 | 1.380 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 10 | 1.330 |
Why?
|
| Angiotensin II | 8 | 2021 | 13 | 1.290 |
Why?
|
| Angiotensin I | 3 | 2020 | 3 | 1.290 |
Why?
|
| Signal Transduction | 10 | 2021 | 225 | 1.270 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 13 | 2007 | 17 | 1.150 |
Why?
|
| Sodium Chloride, Dietary | 3 | 2023 | 6 | 1.140 |
Why?
|
| Natriuresis | 7 | 2017 | 9 | 1.120 |
Why?
|
| Adiposity | 2 | 2019 | 19 | 1.060 |
Why?
|
| Sulfonamides | 2 | 2023 | 8 | 0.890 |
Why?
|
| Male | 27 | 2022 | 2765 | 0.880 |
Why?
|
| Humans | 19 | 2024 | 5477 | 0.870 |
Why?
|
| Oxidative Stress | 3 | 2016 | 59 | 0.870 |
Why?
|
| Interleukin-10 | 2 | 2014 | 9 | 0.840 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 7 | 0.770 |
Why?
|
| Reperfusion Injury | 2 | 2021 | 4 | 0.750 |
Why?
|
| Thiophenes | 2 | 2023 | 6 | 0.750 |
Why?
|
| Podocytes | 1 | 2022 | 30 | 0.740 |
Why?
|
| Cell Line | 8 | 2020 | 86 | 0.730 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 2 | 0.700 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 3 | 0.700 |
Why?
|
| Receptors, Dopamine D1 | 9 | 2011 | 14 | 0.680 |
Why?
|
| Diet, High-Fat | 3 | 2016 | 35 | 0.670 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 44 | 0.660 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2016 | 6 | 0.650 |
Why?
|
| Receptors, Angiotensin | 3 | 2005 | 4 | 0.640 |
Why?
|
| Macrophages | 2 | 2023 | 29 | 0.630 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 242 | 0.630 |
Why?
|
| CD11b Antigen | 1 | 2019 | 2 | 0.610 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 14 | 0.610 |
Why?
|
| Oligopeptides | 4 | 2013 | 8 | 0.610 |
Why?
|
| Insulin | 7 | 2019 | 31 | 0.610 |
Why?
|
| Monocytes | 1 | 2019 | 18 | 0.600 |
Why?
|
| Thinness | 2 | 2011 | 2 | 0.590 |
Why?
|
| Imidazoles | 6 | 2023 | 15 | 0.590 |
Why?
|
| Kidney Cortex | 4 | 2013 | 4 | 0.580 |
Why?
|
| Hyperinsulinism | 5 | 2015 | 6 | 0.580 |
Why?
|
| Antihypertensive Agents | 2 | 2021 | 16 | 0.570 |
Why?
|
| Mice | 7 | 2023 | 719 | 0.570 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2018 | 1 | 0.560 |
Why?
|
| Mice, Inbred C57BL | 5 | 2023 | 195 | 0.560 |
Why?
|
| Vasoconstrictor Agents | 4 | 2017 | 6 | 0.540 |
Why?
|
| Up-Regulation | 3 | 2013 | 30 | 0.480 |
Why?
|
| Liver | 3 | 2015 | 51 | 0.460 |
Why?
|
| Estrogens | 1 | 2015 | 21 | 0.450 |
Why?
|
| Angiotensins | 3 | 2023 | 4 | 0.450 |
Why?
|
| Renin | 4 | 2016 | 4 | 0.420 |
Why?
|
| Kidney Glomerulus | 2 | 2023 | 10 | 0.390 |
Why?
|
| Weight Gain | 1 | 2013 | 28 | 0.390 |
Why?
|
| Sex Characteristics | 1 | 2013 | 26 | 0.390 |
Why?
|
| Pyridines | 5 | 2017 | 24 | 0.380 |
Why?
|
| Sodium | 5 | 2018 | 13 | 0.370 |
Why?
|
| Triglycerides | 3 | 2019 | 7 | 0.370 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2021 | 131 | 0.350 |
Why?
|
| Glucose | 2 | 2010 | 13 | 0.340 |
Why?
|
| Tetrazoles | 2 | 2014 | 4 | 0.340 |
Why?
|
| Benzimidazoles | 2 | 2014 | 10 | 0.330 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Body Weight | 3 | 2019 | 59 | 0.320 |
Why?
|
| Cytokines | 2 | 2021 | 37 | 0.320 |
Why?
|
| Hypoglycemic Agents | 4 | 2007 | 15 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 53 | 0.310 |
Why?
|
| Streptozocin | 2 | 2007 | 6 | 0.310 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2007 | 9 | 0.310 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2020 | 39 | 0.290 |
Why?
|
| Inflammasomes | 2 | 2020 | 39 | 0.280 |
Why?
|
| Dopamine | 4 | 2004 | 26 | 0.270 |
Why?
|
| Ligands | 3 | 2022 | 55 | 0.270 |
Why?
|
| Glycogen | 1 | 2007 | 1 | 0.270 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 1 | 0.270 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2007 | 6 | 0.270 |
Why?
|
| Time Factors | 2 | 2021 | 176 | 0.260 |
Why?
|
| Vasoconstriction | 1 | 2006 | 1 | 0.260 |
Why?
|
| Energy Intake | 2 | 2019 | 10 | 0.250 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 23 | 0.250 |
Why?
|
| Kidney Tubules | 2 | 2003 | 5 | 0.250 |
Why?
|
| Endothelial Cells | 3 | 2020 | 48 | 0.250 |
Why?
|
| Diuresis | 1 | 2004 | 1 | 0.230 |
Why?
|
| GTP-Binding Proteins | 6 | 2007 | 9 | 0.220 |
Why?
|
| Mice, Knockout | 2 | 2016 | 143 | 0.210 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 2 | 2017 | 2 | 0.210 |
Why?
|
| Isoquinolines | 1 | 2023 | 5 | 0.200 |
Why?
|
| Benzhydryl Compounds | 1 | 2023 | 3 | 0.200 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2023 | 1 | 0.200 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 1 | 0.200 |
Why?
|
| Phosphorylation | 8 | 2007 | 50 | 0.200 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2004 | 5 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2022 | 6 | 0.200 |
Why?
|
| Cathepsin L | 1 | 2022 | 2 | 0.190 |
Why?
|
| Diet | 1 | 2023 | 40 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2016 | 6 | 0.190 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 35 | 0.180 |
Why?
|
| Pharmacological Phenomena | 1 | 2021 | 1 | 0.180 |
Why?
|
| Chemokines | 1 | 2021 | 3 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2021 | 17 | 0.170 |
Why?
|
| Drug Synergism | 1 | 2020 | 4 | 0.170 |
Why?
|
| Phenotype | 1 | 2021 | 73 | 0.170 |
Why?
|
| Biphenyl Compounds | 2 | 2014 | 8 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 4 | 0.160 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2020 | 2 | 0.160 |
Why?
|
| RNA, Messenger | 3 | 2022 | 69 | 0.160 |
Why?
|
| Simvastatin | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lysosomes | 1 | 2020 | 21 | 0.160 |
Why?
|
| Uncoupling Protein 1 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Adipose Tissue, Brown | 1 | 2019 | 3 | 0.160 |
Why?
|
| Adiponectin | 1 | 2019 | 3 | 0.160 |
Why?
|
| Adipocytes | 1 | 2019 | 4 | 0.160 |
Why?
|
| Adipose Tissue, White | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cell Size | 1 | 2019 | 6 | 0.160 |
Why?
|
| Epididymis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Body Temperature | 1 | 2019 | 5 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 14 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2019 | 11 | 0.150 |
Why?
|
| THP-1 Cells | 1 | 2019 | 4 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 2 | 0.140 |
Why?
|
| Dopamine Agonists | 5 | 2004 | 9 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 4 | 0.140 |
Why?
|
| Dimerization | 1 | 2018 | 14 | 0.140 |
Why?
|
| Potassium | 1 | 2018 | 4 | 0.140 |
Why?
|
| Epithelial Cells | 3 | 2010 | 31 | 0.140 |
Why?
|
| Cell Membrane | 4 | 2007 | 51 | 0.140 |
Why?
|
| Female | 3 | 2022 | 2811 | 0.140 |
Why?
|
| Methylamines | 1 | 2017 | 4 | 0.140 |
Why?
|
| In Vitro Techniques | 3 | 2006 | 16 | 0.140 |
Why?
|
| Cyclic AMP | 4 | 2006 | 11 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2017 | 49 | 0.130 |
Why?
|
| Systole | 1 | 2016 | 2 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2016 | 15 | 0.130 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 23 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 1 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 30 | 0.120 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 38 | 0.120 |
Why?
|
| Random Allocation | 1 | 2016 | 19 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 19 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 28 | 0.120 |
Why?
|
| Cyclic GMP | 2 | 2006 | 6 | 0.120 |
Why?
|
| Biomarkers | 1 | 2016 | 87 | 0.120 |
Why?
|
| Gene Expression | 2 | 2007 | 52 | 0.120 |
Why?
|
| Sodium-Hydrogen Exchangers | 3 | 2005 | 3 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2016 | 81 | 0.120 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 1 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2013 | 19 | 0.110 |
Why?
|
| Enzyme Inhibitors | 5 | 2006 | 34 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 7 | 0.110 |
Why?
|
| Protein Kinase C | 3 | 2003 | 15 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 5 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 10 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2003 | 12 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2004 | 9 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 21 | 0.100 |
Why?
|
| Gonads | 1 | 2013 | 1 | 0.100 |
Why?
|
| Triiodothyronine | 1 | 2013 | 1 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2013 | 3 | 0.100 |
Why?
|
| Glucose Tolerance Test | 1 | 2013 | 3 | 0.100 |
Why?
|
| Organ Size | 1 | 2013 | 31 | 0.100 |
Why?
|
| Estradiol | 1 | 2013 | 16 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2013 | 18 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2013 | 47 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Homeostasis | 1 | 2011 | 30 | 0.090 |
Why?
|
| Aging | 2 | 2003 | 127 | 0.090 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 2003 | 9 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 11 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 8 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 27 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2020 | 134 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 14 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 16 | 0.080 |
Why?
|
| Bromocriptine | 3 | 2004 | 3 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2007 | 16 | 0.080 |
Why?
|
| Opossums | 2 | 2005 | 2 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2007 | 2 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cytosol | 1 | 2007 | 7 | 0.070 |
Why?
|
| Protein Transport | 1 | 2007 | 30 | 0.070 |
Why?
|
| Potassium Chloride | 1 | 2006 | 1 | 0.060 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 1 | 0.060 |
Why?
|
| Endothelin-1 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2006 | 2 | 0.060 |
Why?
|
| Losartan | 1 | 2006 | 3 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2006 | 2 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 3 | 0.060 |
Why?
|
| Second Messenger Systems | 2 | 2004 | 4 | 0.060 |
Why?
|
| Colforsin | 2 | 2004 | 4 | 0.060 |
Why?
|
| Nitrates | 1 | 2006 | 1 | 0.060 |
Why?
|
| Nitrites | 1 | 2006 | 1 | 0.060 |
Why?
|
| Macrolides | 2 | 2004 | 2 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2006 | 17 | 0.060 |
Why?
|
| Urination | 1 | 2005 | 1 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2004 | 5 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2005 | 18 | 0.060 |
Why?
|
| Binding Sites | 2 | 2022 | 69 | 0.060 |
Why?
|
| Benzazepines | 4 | 2004 | 4 | 0.050 |
Why?
|
| Dopamine Antagonists | 4 | 2004 | 5 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2003 | 1 | 0.050 |
Why?
|
| Type C Phospholipases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Adenylyl Cyclases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 1 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 12 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 4 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 4 | 0.050 |
Why?
|
| Peptides | 1 | 2022 | 51 | 0.050 |
Why?
|
| Mitosis | 1 | 2001 | 2 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 52 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 6 | 0.040 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 11 | 0.040 |
Why?
|
| HMGB1 Protein | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 57 | 0.040 |
Why?
|
| Autophagy | 1 | 2020 | 31 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 21 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2004 | 6 | 0.040 |
Why?
|
| Rats, Inbred F344 | 3 | 2003 | 21 | 0.040 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2017 | 2 | 0.030 |
Why?
|
| Caspase Inhibitors | 1 | 2017 | 2 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2017 | 4 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2017 | 10 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 14 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 24 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 18 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 23 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 2004 | 3 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 2004 | 3 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2004 | 31 | 0.030 |
Why?
|
| Genistein | 2 | 2002 | 5 | 0.020 |
Why?
|
| Flavonoids | 2 | 2002 | 22 | 0.020 |
Why?
|
| Necrosis | 1 | 2004 | 1 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2004 | 2 | 0.010 |
Why?
|
| Microvilli | 1 | 2004 | 2 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 55 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 4 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2003 | 2 | 0.010 |
Why?
|
| Protein Kinase C beta | 1 | 2003 | 3 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 6 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 1 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 4 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 11 | 0.010 |
Why?
|
| Bucladesine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Domperidone | 1 | 2002 | 1 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 1 | 0.010 |
Why?
|
| Vanadates | 1 | 2002 | 1 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 75 | 0.010 |
Why?
|
| Thymidine | 1 | 2001 | 1 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 2 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 16 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2001 | 2 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 183 | 0.010 |
Why?
|